Patents by Inventor Guy CINAMON

Guy CINAMON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12612457
    Abstract: The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.
    Type: Grant
    Filed: August 28, 2024
    Date of Patent: April 28, 2026
    Assignee: Nectin Therapeutics Ltd.
    Inventors: Pinchas Tsukerman, Anas Atieh, Akram Obiedat, Guy Cinamon
  • Publication number: 20260014268
    Abstract: The present invention provides antibody drug conjugates (ADCs) of humanized anti-PVR (CD155) and use thereof in treating diseases, in particular cancer.
    Type: Application
    Filed: September 4, 2023
    Publication date: January 15, 2026
    Applicant: NECTIN THERAPEUTICS LTD.
    Inventors: Pinchas TSUKERMAN, Anas ATIEH, Akram OBIEDAT, Alon VITENSHTEIN, Guy CINAMON
  • Publication number: 20260014269
    Abstract: The present invention provides humanized antibodies against Nectin-4 and antibody drug conjugates (ADCs) of the humanized antibodies and use thereof in treating diseases, in particular cancer.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 15, 2026
    Applicant: NECTIN THERAPEUTICS LTD.
    Inventors: Pinchas TSUKERMAN, Anas ATIEH, Akram OBIEDAT, Alon VITENSHTEIN, Guy CINAMON
  • Publication number: 20240424128
    Abstract: The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 26, 2024
    Inventors: Pinchas Tsukerman, Anas Atieh, Akram Obiedat, Guy Cinamon
  • Publication number: 20240409632
    Abstract: The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 12, 2024
    Inventors: Pinchas Tsukerman, Anas Atieh, Akram Obiedat, Guy Cinamon
  • Publication number: 20240270840
    Abstract: The present invention provides monoclonal antibodies that recognize human CD 112R with high affinity and specificity and inhibit its binding to Nectin-2. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.
    Type: Application
    Filed: February 9, 2022
    Publication date: August 15, 2024
    Applicants: NECTIN THERAPEUTICS LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Pinchas TSUKERMAN, Anas ATIEH, Akram OBIEDAT, Guy CINAMON, Stipan JONJIC, Tihana LENAC ROVIĆ , Paola KUCAN BRLIC, Ofer MANDELBOIM